Cover Image
Market Research Report

Arthritis - Pipeline Review, H2 2014

Published by Global Markets Direct Product code 229756
Published Content info 154 Pages
Immediate Delivery Available
Price
Back to Top
Arthritis - Pipeline Review, H2 2014
Published: July 31, 2014 Content info: 154 Pages
Description

Summary

Global Markets Direct's, 'Arthritis - Pipeline Review, H2 2014', provides an overview of the Arthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arthritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arthritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arthritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Product Code: GMDHC5196IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arthritis Overview
  • Therapeutics Development
    • Pipeline Products for Arthritis - Overview
    • Pipeline Products for Arthritis - Comparative Analysis
  • Arthritis - Therapeutics under Development by Companies
  • Arthritis - Therapeutics under Investigation by Universities/Institutes
  • Arthritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arthritis - Products under Development by Companies
  • Arthritis - Products under Investigation by Universities/Institutes
  • Arthritis - Companies Involved in Therapeutics Development
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Nemucore Medical Innovations, Inc.
    • Taisho Pharmaceutical Co., Ltd.
    • Sylentis S.A.
    • Astellas Pharma Inc.
    • Eisai Co., Ltd.
    • Bone Medical Limited
    • Momenta Pharmaceuticals, Inc.
    • Can-Fite BioPharma Ltd.
    • Lexicon Pharmaceuticals, Inc.
    • CSL Limited
    • WhanIn Pharmaceutical Co., Ltd.
    • Oscotec Inc.
    • Viron Therapeutics, Inc.
    • PLx Pharma Inc.
    • Endocyte, Inc.
    • Cardax Pharmaceuticals, Inc.
    • Taiwan Liposome Company, Ltd.
    • NasVax Ltd.
    • CalciMedica, Inc.
    • Zyngenia, Inc.
    • SelectX Pharmaceuticals, Inc.
    • DoNatur GmbH
    • CellAct Pharma GmbH
    • Arcarios BV
    • Inbiopro Solutions Pvt. Ltd.
    • Sagene Pharmaceuticals, Inc.
    • vida therapeutics inc.
    • Dong-A Socio Group
  • Arthritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • vancomycin hydrochloride - Drug Profile
    • PL-1100 - Drug Profile
    • MCS-18 - Drug Profile
    • GLPG-0555 - Drug Profile
    • LY-3114062 - Drug Profile
    • CSL-324 - Drug Profile
    • VT-346 - Drug Profile
    • CF-602 - Drug Profile
    • CDX-085 - Drug Profile
    • PL-5100 - Drug Profile
    • EC-1496 - Drug Profile
    • AMAP-102 - Drug Profile
    • ABC-294640 - Drug Profile
    • Anti-CD3 Oral Immunotherapy - Drug Profile
    • IBPB-001PH - Drug Profile
    • selegiline + NSAIDs - Drug Profile
    • AS-1940477 - Drug Profile
    • dexamethasone acetate - Drug Profile
    • MDC-917 - Drug Profile
    • Small Molecules to Inhibit MMP - Drug Profile
    • CAP-2.1 - Drug Profile
    • CAP-2.2 - Drug Profile
    • CAP1.1 - Drug Profile
    • Recombinant Protein to Inhibit TNF-Alpha for Inflammatory Diseases - Drug Profile
    • Small Molecules to Inhibit C-Rel for Central Nervous System, Musculoskeletal, Respiratory and Metabolic Disorders - Drug Profile
    • OXT-328 - Drug Profile
    • Peptide to Inhibit Intracellular IL-1 Receptor for Musculoskeletal, Dermatology and Central Nervous System Disorders - Drug Profile
    • Peptides to Inhibit MHC Class I and II for CNS Disorders and Musculoskeletal - Drug Profile
    • Antibody for Autoimmune Disorders and Inflammation - Drug Profile
    • DCB-3503 - Drug Profile
    • AT-132 - Drug Profile
    • TASP-0415914 - Drug Profile
    • fluticasone propionate - Drug Profile
    • Monoclonal Antibody to Inhibit Ang-2 and TNF-a - Drug Profile
    • CIIF-4 - Drug Profile
    • OA-1 - Drug Profile
    • TLC-599 - Drug Profile
    • Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile
    • Small Molecule to Activate S100A8 for Arthritis - Drug Profile
    • CM-3457 - Drug Profile
    • Drugs to Activate P58IPK for Arthritis - Drug Profile
    • IMSB-001 - Drug Profile
    • RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile
    • BN-005 - Drug Profile
    • BN-008 - Drug Profile
    • Small Molecule to Inhibit SYK for Arthritis - Drug Profile
    • Small Molecule to Inhibit ADAMTS-5 for Arthritis - Drug Profile
    • WIP-901C - Drug Profile
    • Small Molecules to Inhibit Cyclophilins - Drug Profile
    • Drug for Chronic Inflammatory Diseases - Drug Profile
    • Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Inflammtion, Arthritis, Cardiovascular Disease and Bleeding Disorders - Drug Profile
    • Peptides to Inhibit TNF-a for Immunology, Oncology and Musculoskeletal Disorders - Drug Profile
    • Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile
    • Small Molecules to Modulate BMP-2 for Arthritis - Drug Profile
    • FIV-based siRNA - Drug Profile
    • Gene Therapy for Arthritis - Drug Profile
    • NMI-4100 - Drug Profile
  • Arthritis - Recent Pipeline Updates
  • Arthritis - Dormant Projects
  • Arthritis - Discontinued Products
  • Arthritis - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arthritis, H2 2014
  • Number of Products under Development for Arthritis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Development by Companies, H2 2014 (Contd..1)
  • Number of Products under Development by Companies, H2 2014 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Development by Companies, H2 2014 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2014
  • Arthritis - Pipeline by Eli Lilly and Company, H2 2014
  • Arthritis - Pipeline by GlaxoSmithKline plc, H2 2014
  • Arthritis - Pipeline by Nemucore Medical Innovations, Inc., H2 2014
  • Arthritis - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014
  • Arthritis - Pipeline by Sylentis S.A., H2 2014
  • Arthritis - Pipeline by Astellas Pharma Inc., H2 2014
  • Arthritis - Pipeline by Eisai Co., Ltd., H2 2014
  • Arthritis - Pipeline by Bone Medical Limited, H2 2014
  • Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014
  • Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by CSL Limited, H2 2014
  • Arthritis - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014
  • Arthritis - Pipeline by Oscotec Inc., H2 2014
  • Arthritis - Pipeline by Viron Therapeutics, Inc., H2 2014
  • Arthritis - Pipeline by PLx Pharma Inc., H2 2014
  • Arthritis - Pipeline by Endocyte, Inc., H2 2014
  • Arthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by Taiwan Liposome Company, Ltd., H2 2014
  • Arthritis - Pipeline by NasVax Ltd., H2 2014
  • Arthritis - Pipeline by CalciMedica, Inc., H2 2014
  • Arthritis - Pipeline by Zyngenia, Inc., H2 2014
  • Arthritis - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by DoNatur GmbH, H2 2014
  • Arthritis - Pipeline by CellAct Pharma GmbH, H2 2014
  • Arthritis - Pipeline by Arcarios BV, H2 2014
  • Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014
  • Arthritis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by vida therapeutics inc., H2 2014
  • Arthritis - Pipeline by Dong-A Socio Group, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Arthritis Therapeutics - Recent Pipeline Updates, H2 2014
  • Arthritis - Dormant Projects, H2 2014
  • Arthritis - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Arthritis, H2 2014
  • Number of Products under Development for Arthritis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top